Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification

Cancer Cell

Volumn 3, Issue 2, 2003, Pages 173-183

  Armstrong, Scott A ^a,b   Kung, Andrew L ^a,b   Mabon, Meghann E ^a   Silverman, Lewis B ^a,b   Stam, Ronald W ^c   Den Boer, Monique L ^c   Pieters, Rob ^c   Kersey, John H ^d   Sallan, Stephen E ^a,b   Fletcher, Jonathan A ^e   Golub, Todd R ^a,f   Griffin, James D ^a,e   Korsmeyer, Stanley J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^d UNIVERSITY OF MINNESOTA   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; ISOENZYME; PROTEIN TYROSINE KINASE; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; DNA BINDING PROTEIN; DRUG DERIVATIVE; FLT3 PROTEIN, HUMAN; FLT3 PROTEIN, MOUSE; INTERLEUKIN 3; LIPOCORTIN 5; MIDOSTAURIN; MIXED LINEAGE LEUKEMIA PROTEIN; MLL PROTEIN, HUMAN; MLL PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN KINASE C; STAUROSPORINE; TRANSCRIPTION FACTOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL CELL; ARTICLE; CYTOTOXICITY; EMBRYO; ENZYME ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENE OVEREXPRESSION; GENE TRANSLOCATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; VALIDATION PROCESS; WILD TYPE; ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL; CELL CULTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; PRESCHOOL CHILD; PROTO ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALIA;

ANIMALS; ANNEXIN A5; ANTINEOPLASTIC AGENTS; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERLEUKIN-3; LEUKEMIA, LYMPHOCYTIC, ACUTE; MICE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENES; RECEPTOR PROTEIN-TYROSINE KINASES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STAUROSPORINE; TRANSCRIPTION FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0013312329     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00003-5     Document Type: Article

References (50)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
2. Arico M., Valsecchi M.G., Camitta B., Schrappe M., Chessells J., Baruchel A., Gaynon P., Silverman L., Janka-Schaub G., Kamps W., et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N. Engl. J. Med. 342:2000;998-1006.
3. Armstrong S.A., Staunton J.E., Silverman L.B., Pieters R., den Boer M.L., Minden M.D., Sallan S.E., Lander E.S., Golub T.R., Korsmeyer S.J. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat. Genet. 30:2002;41-47.
4. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., Ladd C., Beheshti J., Bueno R., Gillette M., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl. Acad. Sci. USA. 98:2001;13790-13795.
5. Burns J.C., Friedmann T., Driever W., Burrascano M., Yee J.K. Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors. concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells Proc. Natl. Acad. Sci. USA. 90:1993;8033-8037.
6. Chen C.S., Sorensen P.H., Domer P.H., Reaman G.H., Korsmeyer S.J., Heerema N.A., Hammond G.D., Kersey J.H. Molecular rearrangements on chromosome 11q23 predominate in infant acute lymphoblastic leukemia and are associated with specific biologic variables and poor outcome. Blood. 81:1993;2386-2393.
7. Cuthbert G., Thompson K., Breese G., McCullough S., Bown N. Sensitivity of FISH in detection of MLL translocations. Genes Chromosomes Cancer. 29:2000;180-185.
8. DaSilva N., Hu Z.B., Ma W., Rosnet O., Birnbaum D., Drexler H.G. Expression of the FLT3 gene in human leukemia-lymphoma cell lines. Leukemia. 8:1994;885-888.
9. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347:2002;472-480.
10. Di Fiore P.P., Pierce J.H., Kraus M.H., Segatto O., King C.R., Aaronson S.A. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science. 237:1987;178-182.
11. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., Sawyers C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344:2001;1031-1037. a.
12. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344:2001;1038-1042. b.
13. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., Behm F.G., Pui C.H., Downing J.R., Gilliland D.G., et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:2002;75-87.
14. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood. 100:2002;1532-1542.
15. Greil J., Gramatzki M., Burger R., Marschalek R., Peltner M., Trautmann U., Hansen-Hagge T.E., Bartram C.R., Fey G.H., Stehr K., et al. The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br. J. Haematol. 86:1994;275-283.
16. Hawley R.G., Lieu F.H., Fong A.Z., Hawley T.S. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1:1994;136-138.
17. Hibbard M.K., Kozakewich H.P., Dal Cin P., Sciot R., Tan X., Xiao S., Fletcher J.A. PLAG1 fusion oncogenes in lipoblastoma. Cancer Res. 60:2000;4869-4872.
18. Inaba T., Roberts W.M., Shapiro L.H., Jolly K.W., Raimondi S.C., Smith S.D., Look A.T. Fusion of the leucine zipper gene HLF to the E2A gene in human acute B-lineage leukemia. Science. 257:1992;531-534.
19. Kelly L.M., Yu J.C., Boulton C.L., Apatira M., Li J., Sullivan C.M., Williams I., Amaral S.M., Curley D.P., Duclos N., et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell. 1:2002;421-432.
20. Kiyoi H., Ohno R., Ueda R., Saito H., Naoe T. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene. 21:2002;2555-2563.
21. Lessnick S.L., Dacwag C.S., Golub T.R. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts. Cancer Cell. 1:2002;393-401.
22. Levis M., Allebach J., Tse K.F., Zheng R., Baldwin B.R., Smith B.D., Jones-Bolin S., Ruggeri B., Dionne C., Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 99:2002;3885-3891.
23. Mackarehtschian K., Hardin J.D., Moore K.A., Boast S., Goff S.P., Lemischka I.R. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 3:1995;147-161.
24. Matthews W., Jordan C.T., Wiegand G.W., Pardoll D., Lemischka I.R. A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell. 65:1991;1143-1152.
25. Meierhoff G., Dehmel U., Gruss H.J., Rosnet O., Birnbaum D., Quentmeier H., Dirks W., Drexler H.G. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 9:1995;1368-1372.
26. Nakao M., Yokota S., Iwai T., Kaneko H., Horiike S., Kashima K., Sonoda Y., Fujimoto T., Misawa S. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 10:1996;1911-1918.
27. Perou C.M., Sorlie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Rees C.A., Pollack J.R., Ross D.T., Johnsen H., Akslen L.A., et al. Molecular portraits of human breast tumours. Nature. 406:2000;747-752.
28. Pocock C.F., Malone M., Booth M., Evans M., Morgan G., Greil J., Cotter F.E. BCL-2 expression by leukaemic blasts in a SCID mouse model of biphenotypic leukaemia associated with the t(4;11)(q21;q23) translocation. Br. J. Haematol. 90:1995;855-867.
29. Pomeroy S.L., Tamayo P., Gaasenbeek M., Sturla L.M., Angelo M., McLaughlin M.E., Kim J.Y., Goumnerova L.C., Black P.M., Lau C., et al. Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature. 415:2002;436-442.
30. Propper D.J., McDonald A.C., Man A., Thavasu P., Balkwill F., Braybrooke J.P., Caponigro F., Graf P., Dutreix C., Blackie R., et al. Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19:2001;1485-1492.
31. Pui C.H., Crist W.M., Look A.T. Biology and clinical significance of cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Blood. 76:1990;1449-1463.
32. Pui C.H., Frankel L.S., Carroll A.J., Raimondi S.C., Shuster J.J., Head D.R., Crist W.M., Land V.J., Pullen D.J., Steuber C.P., et al. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23). a collaborative study of 40 cases Blood. 77:1991;440-447.
33. Rosnet O., Marchetto S., deLapeyriere O., Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 6:1991;1641-1650.
34. Rowley J.D. The critical role of chromosome translocations in human leukemias. Annu. Rev. Genet. 32:1998;495-519.
35. Rubin B.P., Singer S., Tsao C., Duensing A., Lux M.L., Ruiz R., Hibbard M.K., Chen C.J., Xiao S., Tuveson D.A., et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 61:2001;8118-8121.
36. Schulte C.E., von Lindern M., Steinlein P., Beug H., Wiedemann L.M. MLL-ENL cooperates with SCF to transform primary avian multipotent cells. EMBO J. 21:2002;4297-4306.
37. Shipp M.A., Ross K.N., Tamayo P., Weng A.P., Kutok J.L., Aguiar R.C., Gaasenbeek M., Angelo M., Reich M., Pinkus G.S., et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. 8:2002;68-74.
38. Silverman L.B., McLean T.W., Gelber R.D., Donnelly M.J., Gilliland D.G., Tarbell N.J., Sallan S.E. Intensified therapy for infants with acute lymphoblastic leukemia. results from the Dana-Farber Cancer Institute Consortium Cancer. 80:1997;2285-2295.
39. Singh D., Febbo P.G., Ross K., Jackson D.G., Manola J., Ladd C., Tamayo P., Renshaw A.A., D'Amico A.V., Richie J.P., et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell. 1:2002;203-209.
40. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer. correlation of relapse and survival with amplification of the HER-2/neu oncogene Science. 235:1987;177-182.
41. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344:2001;783-792.
42. Small D., Levenstein M., Kim E., Carow C., Amin S., Rockwell P., Witte L., Burrow C., Ratajczak M.Z., Gewirtz A.M., et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc. Natl. Acad. Sci. USA. 91:1994;459-463.
43. Stong R.C., Korsmeyer S.J., Parkin J.L., Arthur D.C., Kersey J.H. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood. 65:1985;21-31.
44. van't Veer L.J., Dai H., van de Vijver M.J., He Y.D., Hart A.A., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 415:2002;530-536.
45. Weisberg E., Boulton C., Kelly L.M., Manley P., Fabbro D., Meyer T., Gilliland D.G., Griffin J.D. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 1:2002;433-443.
46. Wormann B., Anderson J.M., Liberty J.A., Gajl-Peczalska K., Brunning R.D., Silberman T.L., Arthur D.C., LeBien T.W. Establishment of a leukemic cell model for studying human pre-B to B cell differentiation. J. Immunol. 142:1989;110-117.
47. Xu F., Taki T., Eguchi M., Kamada N., Ishii E., Endo M., Hayashi Y. Tandem duplication of the FLT3 gene is infrequent in infant acute leukemia. Japan Infant Leukemia Study Group. Leukemia. 14:2000;945-947.
48. Yamamoto Y., Kiyoi H., Nakano Y., Suzuki R., Kodera Y., Miyawaki S., Asou N., Kuriyama K., Yagasaki F., Shimazaki C., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood. 97:2001;2434-2439.
49. Yee K.W., O'Farrell A.M., Smolich B.D., Cherrington J.M., McMahon G., Wait C.L., McGreevey L.S., Griffith D.J., Heinrich M.C. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood. 100:2002;2941-2949.
50. Yeoh E.J., Ross M.E., Shurtleff S.A., Williams W.K., Patel D., Mahfouz R., Behm F.G., Raimondi S.C., Relling M.V., Patel A., et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 1:2002;133-143.